Infections of the liver and biliary system are not uncommon, while most of the infections are viral in nature. Globally, viral hepatitis is a major public health problem and parallels infections such as HIV and tuberculosis and is associated with significant morbidity and mortality. Rapid advances have been made with HCV therapy at a time when the community focus has shifted to global elimination. This issue highlights some of the areas of considerable advances and challenges in viral hepatitis B and C. In addition, Hepatitis E is resurfacing as an infection of significance, particularly in the Western World where there is a prevalence of chronic infections. Gastroenterologists and hepatologists often think of viral hepatitis as the sole cause of hepatic infections, but there are other infections caused to bacteria, fungi and parasites; this issue highlights these infections as well. Articles are devoted to the following topics: Global epidemiology of viral hepatitis; Update on diagnostics in viral hapatitis; Heptatitis B: Immunization and impact on natural history and cancer incidence; Heptatitis B: Current status of therapy and future therapies; Hepatitis Delta: Prevalence, natural history, and treatment options; Hepatitis C: How good is real-life data and do generics work: Hepatitis C: Does successful treatment alter the natural history and quality of life; Hepatitis E: Epidemiology,clinical course, prevention, and treatment; CMV and EBV infections of the liver; Extrahepatic manifestations of viral hepatitis; Pyogenic and amebic infections of the liver; and Fungal and parasitic infections of the liver.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.